TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Oncolytics Biotech ( (ONCY) ).
Oncolytics Biotech Inc. has established a Gastrointestinal Tumor Scientific Advisory Board to advance pelareorep as a platform immunotherapy for GI cancers, including pancreatic, colorectal, and anal cancers. The advisory board, comprising leading oncology experts, will guide the company’s clinical and regulatory strategy, potentially positioning pelareorep as a pioneering treatment in the field. This initiative underscores pelareorep’s potential to improve outcomes and transform treatment landscapes, with the advisory board playing a crucial role in shaping development strategies and supporting regulatory approval pathways.
The most recent analyst rating on (ONCY) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company targets various cancers, including pancreatic, breast, anal, and colorectal, aiming to convert immunologically ‘cold’ tumors into ‘hot’ ones by activating immune responses. Oncolytics is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors, with some programs receiving Fast Track designation from the FDA.
Average Trading Volume: 1,032,707
Technical Sentiment Signal: Hold
Current Market Cap: $105.3M
For detailed information about ONCY stock, go to TipRanks’ Stock Analysis page.